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ABSTRACT 
Enhancers play a central role in cell-type-specific gene expression and are marked by 
H3K4me1/2. Active enhancers are further marked by H3K27ac. However, the 
methyltransferases responsible for H3K4me1/2 on enhancers remain elusive. Furthermore, how 
these enzymes function on enhancers to regulate cell-type-specific gene expression is unclear. 
Here we identify MLL4 (KMT2D) as a major mammalian H3K4 mono- and di-methyltransferase 
with partial functional redundancy with MLL3 (KMT2C). Using adipogenesis and myogenesis 
as model systems, we show that MLL4 exhibits cell-type- and differentiation-stage-specific 
genomic binding and is predominantly localized on enhancers. MLL4 co-localizes with lineage-
determining transcription factors (TFs) on active enhancers during differentiation. Deletion of 
MLL4 markedly decreases H3K4me1/2, H3K27ac, Mediator and Polymerase II levels on 
enhancers and leads to severe defects in cell-type-specific gene expression and cell 
differentiation. Together, these findings identify MLL4 as a major mammalian H3K4 mono- and 
di-methyltransferase essential for enhancer activation during cell differentiation. 
 
HIGHLIGHTS 
 MLL3/MLL4 (KMT2C/KMT2D) are major mammalian H3K4me1/2 methyltransferases. 
 MLL4 co-localizes with lineage-determining TFs on active enhancers. 
 MLL4 is required for enhancer activation and cell-type-specific gene expression.  
 Lineage-determining TFs recruit and require MLL4 to establish enhancers. 
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INTRODUCTION 
Enhancers are gene regulatory elements critical for cell-type-specific gene expression in 
eukaryotes (Bulger and Groudine, 2011). Lineage-determining or signal-dependent transcription 
factors (TFs) bind to enhancers and recruit chromatin modifying and remodeling enzymes and 
the Mediator coactivator complex to initiate RNA polymerase II (Pol II)-mediated transcription 
at promoters (Roeder, 2005). Recent genome-wide analyses of histone modifications, binding of 
transcription coactivators p300 and MED1 and lineage-determining TFs, coupled with functional 
assays of gene regulatory elements, have enabled the identification of enhancer chromatin 
signatures (Creyghton et al., 2010; Ernst et al., 2011; Ghisletti et al., 2010; Heintzman et al., 
2009; Heintzman et al., 2007; Heinz et al., 2010; Lupien et al., 2008; Rada-Iglesias et al., 2011; 
Visel et al., 2009; Wang et al., 2008). In contrast to active promoters which are marked by 
H3K4me3, enhancers are marked by H3K4me1 and H3K4me2 (H3K4me1/2) but little 
H3K4me3, and are often bound by cell-type-specific TFs. Active enhancers are further marked 
by histone acetyltransferases CBP/p300-mediated H3K27ac (Creyghton et al., 2010; Rada-
Iglesias et al., 2011). H3K4me1 on enhancers often precedes H3K27ac and activation of 
enhancers. A large number of recent publications have validated the predictive power of such 
enhancer chromatin signatures in identification of novel enhancers critical for cell-type-specific 
gene expression and cell differentiation (reviewed in (Calo and Wysocka, 2013)). 
 In yeast, the Set1 complex is the sole H3K4 methyltransferase. Through the enzymatic 
subunit SET1, it is responsible for all mono-, di- and tri-methylations on H3K4 (Ruthenburg et 
al., 2007). In Drosophila, there are three Set1-like H3K4 methyltransferase complexes that use 
dSet1, Trithorax (Trx) and Trithorax-related (Trr) as the respective enzymatic subunits (Mohan 
et al., 2011). Mammals possess six Set1-like H3K4 methyltransferase complexes (Figure 1 - 
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figure supplement 1A). Based on the sequence homology of enzymatic subunits and the subunit 
compositions (Cho et al., 2007; Cho et al., 2012; Ruthenburg et al., 2007; Vermeulen and 
Timmers, 2010), they fall into three sub-groups: MLL1/MLL2 (also known as KMT2A and 
KMT2B, respectively), MLL3/MLL4 (MLL3 is also known as KMT2C; MLL4 is also known as 
KMT2D, ALR and sometimes MLL2), and SET1A/SET1B (also known as KMT2E and KMT2F, 
respectively), which correspond to Drosophila dSet1, Trx and Trr complexes, respectively. dSet1 
is responsible for the bulk of H3K4me3 in Drosophila (Ardehali et al., 2011; Mohan et al., 2011). 
Consistently, depletion of the unique CFP1 subunit of SET1A/SET1B complexes in mammalian 
cells markedly decreases global H3K4me3 level, suggesting that SET1A/SET1B are the major 
H3K4 tri-methyltransferases in mammals (Clouaire et al., 2012). In contrast, knockdown of Trr, 
the Drosophila homolog of MLL3/MLL4, decreases global H3K4me1 levels, indicating that Trr 
regulates H3K4me1 in Drosophila (Ardehali et al., 2011; Mohan et al., 2011). However, the 
histone methyltransferases (HMTs) responsible for H3K4me1/2 on mammalian enhancers 
remain elusive. Further, the functions of these H3K4 mono-/di-methyltransferases on enhancers 
and in regulating cell-type-specific gene induction and cell differentiation are unclear. Finally, 
how these HMTs are recruited to enhancers needs to be clarified (Calo and Wysocka, 2013). 
Adipogenesis and myogenesis are robust and synchronized models of cell differentiation.  
Differentiation of preadipocytes towards adipocytes, i.e. adipogenesis, is regulated by a network 
of sequentially expressed adipogenic TFs (Rosen and MacDougald, 2006). Peroxisome 
Proliferator-Activated Receptor-γ (PPARγ) is considered the master regulator of adipogenesis 
and controls adipocyte gene expression cooperatively with CCAAT/enhancer-binding protein-α 
(C/EBPα) (Lefterova et al., 2008; Rosen et al., 2002). The early adipogenic TF C/EBPβ marks a 
large number of TF ‘hotspots’ before induction of adipogenesis. C/EBP  not only controls the 
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induction of PPAR  and C/EBP  expression but also acts as a pioneer factor to facilitate the 
genomic binding of PPAR , C/EBP  and other adipogenic TFs during adipogenesis (Siersbaek 
et al., 2011). Adipogenesis in cell culture is synchronized, with the vast majority of cells in the 
confluent population differentiating into adipocytes within 6-8 days, thus providing a robust 
model system for studying transcriptional and epigenetic regulation of gene expression during 
cell differentiation (Ge, 2012). Myogenesis is another robust model system for cell 
differentiation. Ectopic expression of the myogenic TF MyoD in fibroblasts and preadipocytes is 
sufficient to induce muscle differentiation program characterized by expression of myogenesis 
markers such as myogenin (Myog) and myosin (Lassar et al., 1991; Tapscott et al., 1988).  
Using adipogenesis and myogenesis as model systems, here we show MLL4 is partially 
redundant with MLL3 and is required for cell differentiation and cell-type-specific gene 
expression. By ChIP-Seq analyses, we observe cell-type- and differentiation-stage-specific 
genomic binding of MLL4. MLL4 is mainly localized on enhancers and co-localizes with 
lineage-determining TFs on active enhancers during differentiation. We demonstrate that MLL4 
is partially redundant with MLL3 and is a major H3K4 mono- and di-methyltransferase in mouse 
and human cells. Furthermore, MLL4 is required for H3K4me1/2, H3K27ac, Mediator and Pol II 
levels on active enhancers, indicating that MLL4 is required for enhancer activation. Finally, we 
provide evidence to suggest that lineage-determining TFs recruit and require MLL4 to establish 
cell-type-specific enhancers.   
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RESULTS 
MLL4 is essential for adipogenesis and myogenesis 
Among the six SET1-like H3K4 methyltransferases found in mammals, we initially knocked out 
MLL3 and MLL4 individually in mice using gene trap approaches (Figure 1 - figure supplement 
1A-E and data not shown). MLL3 knockout (KO) mice died around birth with no obvious 
morphological abnormalities in embryonic development. MLL4 KO mice showed early 
embryonic lethality around E9.5. We then generated MLL4 conditional KO mice (MLL4
f/f
) 
(Figure 1A-B), which were viable and allowed us to investigate MLL4 function in a tissue-
specific manner. Conditional KO of MLL4 was also verified in cell culture. Deletion of MLL4 
led to the disruption of MLL4 complex in cells (Figure 1 - figure supplement 2A-B). 
 To understand the role of MLL4 in adipogenesis and myogenesis, we generated 
MLL4
f/f
;Myf5-Cre mice by crossing MLL4
f/f
 with Myf5-Cre mice (Tallquist et al., 2000). Myf5-
Cre specifically deletes genes flanked by loxP sites in somitic precursor cells that give rise to 
both brown adipose tissue (BAT) and skeletal muscle in the back (Seale et al., 2008). 
MLL4
f/f
;Myf5-Cre pups and E18.5 embryos were obtained at the expected Mendelian ratio but 
displayed marked reduction in back muscles and died immediately after birth due to breathing 
malfunction that is controlled by muscle groups in the rib cage (Figure 1C-D and data not 
shown). Sagittal sections along the midline of E18.5 embryos were subjected to 
immunohistochemistry analysis using antibodies against BAT marker UCP1 and muscle marker 
myosin (Figure 1E). Compared with littermate controls and MLL3 KO, MLL4
f/f
;Myf5-Cre 
embryos showed marked decreases of BAT and muscle mass, suggesting that MLL4 is required 
for adipogenesis and myogenesis. 
 To understand how MLL4 regulates BAT development, we induced adipogenesis in 
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brown preadipocytes in culture. KO of MLL4 led to a moderate differentiation defect along with 
a transient up-regulation of MLL3 expression in the early phase of adipogenesis whereas KO of 
MLL3 had no effect on adipogenesis (Figure 2 - figure supplement 1A-F), suggesting a more 
prominent role of MLL4 in development and a partial compensation of MLL4 loss by MLL3. To 
eliminate the compensatory effect, we isolated primary brown preadipocytes from E18.5 MLL3
-/-
MLL4
f/f
 embryos. After SV40T immortalization (Wang et al., 2010), cells were infected with 
adenoviral Cre (Ad-Cre) or GFP (Ad-GFP) to generate MLL3
-/-
MLL4
-/-
 and MLL3
-/-
 cells, 
respectively. Deletion of MLL4 by Cre from the immortalized MLL3
-/-
MLL4
f/f
 brown 
preadipocytes had little effect on cell growth (Figure 2 - figure supplement 1G-H), but led to 
severe defects in adipogenesis and associated expression of adipogenesis markers and key 
regulators PPARγ and C/EBP  as well as brown adipocyte markers PRDM16 and UCP1 (Figure 
2A-B and Figure 2 - figure supplement 1I), indicating that MLL3 and MLL4 are functionally 
redundant and are essential for adipogenesis. Furthermore, ectopic expression of PPARγ or 
C/EBPβ failed to rescue adipogenesis in MLL3/MLL4 double KO preadipocytes (Figure 2 - 
figure supplement 1J and Figure 2C). Consistent with the results from brown preadipocytes, 
knockdown of MLL4 in 3T3-L1 white preadipocytes inhibited adipogenesis (Figure 2 - figure 
supplement 1K-M). Furthermore, MLL3/MLL4 were also required for PPARγ-stimulated 
adipogenesis in mouse embryonic fibroblasts (MEFs) (Figure 2 – figure supplement 1N-P). 
 To understand how MLL4 regulates myogenesis, we used retroviral vector to stably 
express ectopic MyoD in MLL3
-/-
MLL4
f/f
 brown preadipocytes. Cells were then infected with 
adenoviral Cre or GFP, followed by induction of myogenesis (Figure 2F-H). We found that 
deletion of MLL4 from MLL3
-/-
MLL4
f/f
 brown preadipocytes led to severe defects in MyoD-
stimulated myogenesis of preadipocytes and the associated expression of myogenesis markers 
 8 
 
such as Myog, Myh and Mck. Taken together, these data indicate that MLL4 is essential for 
adipogenesis and myogenesis.   
 
MLL4 controls induction of cell-type-specific genes during differentiation 
Next, we investigated how MLL4 regulates gene expression during differentiation. Adipogenesis 
was induced in Ad-GFP- or Ad-Cre-infected MLL3
-/-
MLL4
f/f
 brown preadipocytes. Samples were 
collected before (day 0) and during (day 2) adipogenesis for RNA-Seq (Figure 2D and Figure 2 - 
figure supplement 2). In total there were 14,902 genes expressed in Ad-GFP-infected cells at 
either time point. Among them, 1,175 (7.9%) and 1,302 (8.7%) showed over 2.5-fold down- and 
up-regulation, respectively, from day 0 to day 2. Among the 1,302 up-regulated genes, a 
significant number (588, p = 1.4E-268, hypergeometric test) was induced in an MLL4-dependent 
manner. Strikingly, gene ontology (GO) analysis revealed that only the MLL4-dependent up-
regulated gene group was associated with fat cell differentiation (Figure 2E), suggesting that 
MLL4 selectively regulates the induction of adipogenesis genes.  
  RNA-Seq analysis of myogenesis of MyoD-expressing brown preadipocytes revealed a 
similar trend. 1,108 (6.6%) and 2,774 (16.5%) genes showed over 2.5-fold down- and up-
regulation, respectively, from brown preadipocytes to myocytes (Figure 2I). Among the 2,774 
up-regulated genes, a significant number (836, p < 1E-300, hypergeometric test) was induced in 
an MLL4-dependent manner. Furthermore, among those gene groups, only the MLL4-dependent 
up-regulated gene group was highly associated with muscle development (Figure 2J). Together, 
these results indicate that MLL4 is required for induction of cell-type-specific genes during 
differentiation. 
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Cell-type- and differentiation-stage-specific genomic binding of MLL4 
  To find out whether MLL4 directly regulates the induction of cell-type-specific genes 
during differentiation, we performed ChIP-Seq of MLL4 in adipogenesis and myogenesis using 
an anti-MLL4 antibody. To exclude false-positive MLL4 targets as a result of off-target antibody 
binding, ChIP-Seq was done in both Ad-GFP- and Ad-Cre-infected MLL3
-/-
MLL4
f/f
 cells (i.e. 
MLL3 KO and MLL3/MLL4 double KO cells). High-confidence MLL4 binding signals were 
obtained by filtering out non-specific signals observed in MLL4-deficient cells (Figure 3 - figure 
supplement 1A-E). ChIP-Seq results were independently verified by quantitative ChIP assays at 
MLL4
+
 regions on multiple adipogenesis genes (Figure 3 - figure supplement 2). 
  ChIP-Seq of MLL4 in adipogenesis was done at 3 time points, day 0 (preadipocytes), day 
2 (during adipogenesis) and day 7 (adipocytes). We identified 6,937, 14,581 and 25,005 high-
confidence MLL4 genomic binding regions at day 0, day 2 and day 7, respectively (Figure 3A). 
The average length of MLL4 binding regions was 350-400bp. Interestingly, MLL4 binding 
regions changed dramatically from day 0 to day 2 but were largely maintained from day 2 to day 
7, suggesting differentiation-stage-specific genomic binding of MLL4 during adipogenesis 
(Figure 3A). ChIP-Seq of MLL4 in myocytes identified 26,581 high-confidence MLL4 genomic 
binding regions. The MLL4-binding regions in adipocytes and myocytes were largely non-
overlapping (Figure 3B), suggesting cell-type-specific genomic binding of MLL4. 
  Cell-type- and differentiation-stage-specific genomic binding of MLL4 was confirmed on 
gene loci encoding the adipogenic TF PPARγ and the myogenic TF Myog (Figure 3C). MLL4 
was also found to bind gene loci encoding other adipogenesis markers such as C/EBPα, KLF15, 
aP2 (Fabp4), LPL and UCP1 at day 2 and day 7 of adipogenesis (Figure 3 - figure supplement 
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1F-K). Interestingly, MLL4 was largely absent from the gene locus encoding the pioneer 
adipogenic TF C/EBPβ.  
  To identify MLL4-associated genes, we used proximity to assign the top 2,000 emergent 
MLL4 binding regions at each time point to the nearest genes. GO analysis of MLL4-associated 
genes identified brown fat cell differentiation and fat cell differentiation as the top two functional 
categories at day 2 (during adipogenesis) and day 7 (adipocytes) but not at day 0 (preadipocytes) 
or in myocytes (Figure 3D). GO analysis also identified muscle organ/tissue development and 
muscle cell differentiation as the top functional categories specifically in myocytes (Figure 3D). 
These results are consistent with GO analysis of RNA-Seq data and suggest that cell-type- and 
differentiation-stage-specific genomic binding of MLL4 is directly involved in the regulation of 
genes critical for cell differentiation. 
 
Genomic co-localization of MLL4 with lineage-determining TFs during differentiation 
Next, we performed motif analysis of the top 2,000 emergent MLL4 binding regions at each time 
point (Figure 4A). At preadipocyte stage before adipogenesis (day 0), MLL4 binding regions 
were enriched with motifs of TFs functioning in various developmental lineages. However, at 
day 2 and day 7 of adipogenesis, MLL4 binding regions were highly enriched with motifs of 
major adipogenic TFs, including C/EBPα, C/EBPβ, PPARγ, EBF1 and GR (Ge, 2012; Rosen and 
MacDougald, 2006). In myocytes, MLL4 binding regions were highly enriched with motifs of 
myogenic TF MyoD and its binding partner TCF3 (also known as E2A) (Lassar et al., 1991), as 
well as myogenic TFs Runx1 and TEAD4 (MacQuarrie et al., 2013).   
  To experimentally validate the predicted motifs, we performed ChIP-Seq of C/EBPα, 
C/EBPβ and PPARγ at day 2 of adipogenesis and of MyoD in myocytes. By comparing the 
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genomic localizations of MLL4 with those of C/EBPα, C/EBPβ and PPARγ, we found that 
consistent with the motif analysis, ~64% of MLL4 binding regions overlapped with those of 
C/EBP /  or PPARγ at day 2 of adipogenesis (Figure 4B-C). In particular, genomic co-
localization of MLL4 with C/EBPα, C/EBPβ and PPARγ was observed on PPARγ and C/EBPα 
loci at day 2 but not day 0 of adipogenesis (Figure 4 - figure supplement 1 and 2). In myocytes, 
40% of MLL4 binding regions overlapped with those of MyoD (Figure 4D-E). Consistent with 
these results, we observed a physical interaction of MLL4 with C/EBPβ during adipogenesis 
(Figure 4F). We also found that PPARγ associated with MLL3/MLL4-containing H3K4 
methyltransferase complex in cells (Figure 4 - figure supplement 3), which is consistent with the 
reported direct interaction between PPAR  and MLL3/MLL4 complex (Lee et al., 2008). 
Together, these results indicate significant genomic co-localization of MLL4 with lineage-
determining TFs during adipogenesis and myogenesis.  
  
MLL4 co-localizes with lineage-determining TFs on active enhancers during differentiation  
To characterize the genomic features of MLL4 binding regions during differentiation, we 
performed ChIP-Seq of H3K4me1/2/3, H3K27ac and Pol II during adipogenesis. Then, we used 
histone marks to define 4 types of gene regulatory elements: active enhancer, silent enhancer, 
active promoter and silent promoter (Figure 5A) (Creyghton et al., 2010; Rada-Iglesias et al., 
2011). Average profile plots revealed that at day 2 of adipogenesis, MLL4 and adipogenic TFs 
C/EBPα, C/EBPβ and PPARγ were enriched on active enhancers (Figure 5B). Genomic 
distribution analyses showed that among the 14,581 MLL4 binding regions at day 2 of 
adipogenesis, 9,642 (66.1%) and 1,836 (12.6%) were located on active and silent enhancers 
while only 451 (3.1%) and 29 (0.2%) were located on active and silent promoters, respectively, 
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indicating that MLL4 mainly bound to enhancers and preferentially active enhancers (p < 1E-300, 
binomial test) (Figure 5C).   
 Genomic distribution analyses also revealed preferential localization of C/EBPs and 
PPARγ on active enhancers during adipogenesis (Figure 5C). Interestingly, 57.3% of the C/EBP-
binding and 80.0% of the PPARγ-binding active enhancers were MLL4+, significantly higher 
than the genome-wide level of co-localization (31.3% for C/EBPs and 56.3% for PPARγ, 
respectively), indicating that MLL4 preferentially co-localizes with these TFs on active 
enhancers than on other genomic locations (p < 1E-300 for either C/EBPs or PPARγ, 
hypergeometric test). 
 At day 2 of adipogenesis, 11,280 active enhancers were bound with adipogenic TFs 
C/EBPα, C/EBPβ or PPAR . These 11,280 active enhancers, which we termed adipogenic 
enhancers, could be clustered into 3 groups: C/EBP
+
PPAR  (C/EBP - or -positive but PPAR -
negative, 8,098 active enhancers), C/EBP PPARγ+ (1,219), and C/EBP+PPARγ+ (1,963) (Figure 
5D). MLL4 binding was found on 46.9% and 61.7% of C/EBP
+
PPAR  and C/EBP PPARγ+ 
adipogenic enhancers, respectively. Remarkably, MLL4 binding was found on 91.3% of 
C/EBP
+PPARγ+ adipogenic enhancers, which were high-confidence adipogenic enhancers 
(Lefterova et al., 2008) (Figure 5D).  
 Similarly, MLL4 and the myogenic TF MyoD were enriched on active enhancers in 
myocytes (Figure 5 - figure supplement 1A-B). We identified 8,091 myogenic enhancers, which 
were active enhancers bound with MyoD. Among the 8,091 myogenic enhancers, 5,228 (64.6%, 
p < 1E-300, hypergeometric test) were MLL4
+
 (Figure 5 - figure supplement 1C). Together, 
these results indicate that MLL4 co-localizes with lineage-determining TFs on active enhancers 
during differentiation.  
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MLL3 and MLL4 are major H3K4 mono- and di-methyltransferases in cells 
  The enrichment of H3K4 methyltransferase MLL4 on active enhancers, which are 
marked by H3K4me1/2 and H3K27ac, prompted us to examine the enzymatic properties of 
MLL4. For this purpose, we affinity-purified endogenous SET1A/SET1B complex 
(SET1A/B.com) and MLL3/MLL4 complex (MLL3/4.com) from 293 cells expressing FLAG-
tagged CFP1 and PA1, the unique subunit of SET1A/B.com and MLL3/4.com, respectively (Cho 
et al., 2007; Lee and Skalnik, 2005). In an in vitro HMT assay using core histones as substrate, 
we found that compared with SET1A/B.com, the major H3K4 tri-methyltransferase in 
mammalian cells, MLL3/4.com carried much stronger mono- and di-methyltransferase activities 
but much weaker tri-methyltransferase activity on H3K4 (Figure 6A). Time-course HMT assays 
confirmed H3K4me1/2 methyltransferase activity of MLL3/4.com in vitro (Figure 6B).  
  In MLL3 single KO brown preadipocytes, we observed a moderate decrease of H3K4me1 
(Figure 6 - figure supplement 1A). Deletion of MLL4 from MLL3
-/-
MLL4
f/f
 cells led to global 
decreases of H3K4me1 and H3K4me2 but much less effect on H3K4me3 levels at day 0 and day 
2 of adipogenesis. H3K27ac levels also decreased significantly (Figure 6C). In MLL3/MLL4 
double KO myocytes and colon cancer cells (Guo et al., 2012), we also observed significant 
decreases of H3K4me1 (Figure 6 - figure supplement 1B and Figure 6D). ChIP-Seq analyses of 
MLL4 and histone modifications also revealed that among the 14,581 MLL4 binding sites during 
adipogenesis, 12,783 (87.7%) were marked by both H3K4me1 and H3K4me2 (Figure 6E). These 
data indicate that endogenous MLL3 and MLL4 are major H3K4 mono- and di-
methyltransferases in mammalian cells. 
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MLL4 is required for enhancer activation and cell-type-specific gene expression during 
differentiation 
The enrichment of H3K4 mono- and di-methyltransferase MLL4 on active enhancers 
during differentiation prompted us to investigate whether MLL4 is required for H3K4me1/2 on 
these enhancers. ChIP-Seq analyses revealed a dramatic increase of MLL4 levels on the 6,342 
MLL4
+
 adipogenic enhancers from day 0 to day 2 of adipogenesis (Figure 7A). Consistently, we 
observed marked increases of H3K4me1/2 on these enhancers. H3K27ac, Mediator (represented 
by the MED1 subunit) and Pol II levels also increased markedly on MLL4
+
 adipogenic 
enhancers from day 0 to day 2. Deletion of MLL4 from MLL3
-/-
MLL4
f/f
 cells prevented the 
marked increases of not only H3K4me1/2 but also H3K27ac, Mediator and Pol II on the 6,342 
MLL4
+
 adipogenic enhancers from day 0 to day 2 (Figure 7A). On PPARγ and C/EBPα gene loci, 
deletion of MLL4 also prevented the increases of H3K4me1/2, H3K27ac, Mediator and Pol II on 
MLL4
+
 adipogenic enhancers during adipogenesis (Figure 4 - figure supplement 1 and 2). On the 
480 MLL4
+
 promoters identified during adipogenesis, MLL4 was required for H3K4me1/2 but 
not H3K4me3 levels. However, the effect of MLL4 deletion on promoter H3K4me1/2 is not as 
severe as on enhancers (Figure 7 - figure supplement 1 vs. Figure 7A). 
During myogenesis, MLL4 and MyoD levels increased dramatically on the 5,228 MLL4
+
 
myogenic enhancers. Deletion of MLL4 from MLL3
-/-
MLL4
f/f
 cells also prevented the marked 
increases of H3K4me1 and H3K27ac on MLL4
+
 myogenic enhancers during myogenesis (Figure 
7 - figure supplement 2A-B). Thus, MLL4 is the major H3K4 mono- and di-methyltransferase on 
adipogenic and myogenic enhancers. Because H3K27ac is a mark for active enhancers, these 
results indicate that MLL4 is required for activation of cell-type-specific enhancers during 
adipogenesis and myogenesis. 
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We next asked how MLL4 affects the induction and expression of genes regulated by 
cell-type-specific enhancers. To focus on the direct effect of MLL4, we examined genes 
associated with MLL4
+
 adipogenic enhancers (C/EBP
+
PPAR , C/EBP PPARγ+, or 
C/EBP
+
PPAR
+
). We first looked at the induction of genes from day 0 to day 2 of adipogenesis 
(Figure 7B). Genes associated with MLL4
+
 adipogenic enhancers at day 2 were better induced 
than those associated with MLL4  adipogenic enhancers (p = 1.5E-22, Wilcoxon test). The 
induction was even stronger if the associated MLL4
+
 adipogenic enhancers were C/EBP
+
PPAR
+
 
(p = 1.5E-76, Wilcoxon test). We then examined how MLL4 affects expression of genes at day 2 
of adipogenesis. As shown in Figure 7C, deletion of MLL4 significantly decreased expression of 
genes associated with MLL4
+
 adipogenic enhancers (C/EBP
+
PPAR  or C/EBP PPARγ+, p = 
2.2E-10, Wilcoxon test). An even stronger effect of MLL4 deletion was observed if the 
associated MLL4
+
 adipogenic enhancers were C/EBP
+
PPAR
+
 (p = 1.8E-31, Wilcoxon test). In 
contrast, deletion of MLL4 had little effect on the expression of genes associated with MLL4  
adipogenic enhancers. In myocytes, deletion of MLL4 significantly decreased expression of 
genes associated with MLL4
+
 myogenic enhancers but not those associated with MLL4  
myogenic enhancers (Figure 7 - figure supplement 2C). Together, these results indicate that 
MLL4 is required for activation of enhancers that are important for cell-type-specific gene 
expression during differentiation. 
 
C/EBPβ recruits and requires MLL4 to establish a subset of adipogenic enhancers 
The physical interaction and the genome-wide co-localization of C/EBP  with MLL4 during 
adipogenesis suggest that the early adipogenic TF C/EBPβ may recruit MLL4 to establish at 
least a subset of adipogenic enhancers. To directly test this possibility, we ectopically expressed 
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C/EBPβ in preadipocytes (Figure 8A), followed by ChIP-Seq of C/EBPβ, MLL4, H3K4me1 and 
H3K27ac without inducing differentiation. Of the 4,965 C/EBPβ+ MLL4+ active enhancers 
identified at day 2 of adipogenesis, 66.6% (3,309/4,965) were bound by ectopic C/EBP  in 
undifferentiated preadipocytes. Ectopic C/EBP  was able to recruit MLL4 to a subset of 
enhancers (666 out of 3,309) (Figure 8B). Among them, 88.7% (591/666) showed the 
characteristics of active enhancers, as indicated by the presence of H3K4me1 and H3K27ac 
(Figure 8C). Among the 591 recovered C/EBPβ+ MLL4+ active enhancers, 375 displayed ectopic 
C/EBP -induced de novo MLL4 binding, which led to significant increases of H3K4me1 and 
H3K27ac. The remaining 216 recovered C/EBPβ+ MLL4+ adipogenic enhancers, which were 
pre-marked by MLL4 in the control cells, showed ectopic C/EBP -enhanced MLL4 binding as 
well as H3K4me1 and H3K27ac (Figure 8C). Importantly, deletion of MLL4 markedly decreased 
H3K4me1 and H3K27ac on over 90% of the 591 recovered C/EBPβ+ MLL4+ adipogenic 
enhancers (Figure 8C - D). MLL4-dependent de novo H3K4me1 and H3K27ac were also 
observed on the C/EBPβ+ adipogenic enhancers located on PPAR  gene locus (Figure 8E). 
Together, these results suggest that lineage-determining TF C/EBPβ recruits and requires MLL4 
to establish at least a subset of adipogenic enhancers. 
  Consistently, by quantitative time-course ChIP assays performed during the first 48h of 
adipogenesis, we observed sequential enrichments of lineage-determining TF C/EBP , 
H3K4me1/2 methyltransferase MLL4, H3K4me1/2, and H3K27ac on C/EBPβ+MLL4+ 
adipogenic enhancers identified on PPAR  gene locus (Figure 8 - figure supplement 1). 
Combined with our earlier observations, these results suggest a step-wise model of enhancer 
activation during cell differentiation (Figure 8G and Discussion).    
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DISCUSSION 
In this paper, we identify MLL4 as a major H3K4 mono- and di-methyltransferase 
enriched on mammalian enhancers. We show MLL4 is essential for enhancer activation, cell-
type-specific gene expression, and cell differentiation. Our findings also shed new light on how 
histone modifying enzymes coordinate with lineage-determining transcription factors on 
enhancers to regulate gene expression and cell differentiation. 
 
MLL4 is a major H3K4me1/2 methyltransferase on mammalian enhancers 
Drosophila Trr and its mammalian homologs MLL3/MLL4 represent the major candidate 
methyltransferases for H3K4me1 on enhancers (Calo and Wysocka, 2013). Our in vitro HMT 
assays show that MLL3/4.com carries predominantly H3K4 mono- and di-methyltransferase 
activity with little H3K4 tri-methyltransferase activity, in agreement with two recent studies 
(Tang et al., 2013; Wu et al., 2013). By generating MLL3/MLL4 double KO cells, we 
demonstrate that endogenous MLL3 and MLL4 are major H3K4me1/2 methyltransferases in 
mammalian cells and that MLL4 has a partial functional redundancy with MLL3 in cells.  
False-positive signals due to potential cross-reactivity of antibodies are a major concern 
in ChIP-Seq analyses (Kidder et al., 2011). In order to exclude false-positive signals and identify 
bona fide MLL4 binding regions, we performed ChIP-Seq of MLL4 in both MLL3 KO and 
MLL3/MLL4 double KO cells. The results provide the direct evidence that MLL4 is a major 
H3K4me1/2 methyltransferase on enhancers during cell differentiation. More importantly, our 
data indicates that MLL4 is required for enhancer activation, which suggests that H3K4me1/2 
may be important for enhancer activation. The partial functional redundancy between MLL3 and 
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MLL4 in cells suggests that endogenous MLL3 is likely an H3K4me1/2 methyltransferase on 
enhancers and is likely involved in the activation of cell-type-specific enhancers. 
Significant levels of H3K4me1/2 remain in MLL3/MLL4 double KO cells (Figure 6C), 
indicating that other H3K4 methyltransferases contribute to H3K4me1/2 in cells. Studies have 
shown possible roles of MLL1 and Set7 in catalyzing H3K4me1 on specific enhancers (Blum et 
al., 2012; Kaikkonen et al., 2013), but whether these enzymes are required for enhancer 
activation remains to be determined. It was shown recently that knockdown of several H3K4 
methyltransferases including MLL1, MLL3, MLL4 in macrophages led to significant decreases 
of H3K4me1/2 on latent enhancers (Kaikkonen et al., 2013). Our data indicates that MLL4 is 
required for the activation of cell-type-specific enhancers during differentiation. Whether MLL4 
is also required for the activation of latent enhancers remains to be determined. 
 
Lineage-determining TFs recruit MLL4 to establish cell type-specific enhancers 
During adipogenesis and myogenesis, MLL4 exhibits cell-type- and differentiation-stage-
specific genomic binding and co-localizes with lineage-determining TFs and H3K4me1/2 on 
active enhancers. Thus, MLL4 appears to mark lineage-determining enhancers during 
differentiation. It will be interesting to test whether MLL4 binding can predict enhancers in other 
cell types. Interestingly, MLL4-dependent H3K4me1/2 distribute well beyond the binding sites 
of lineage-determining TFs and MLL4. A similar observation can be made for p300 and 
H3K27ac (Rada-Iglesias et al., 2011), where H3K27ac is distributed much broader than p300. 
We speculate that lineage-determining TFs along with MLL4 may induce physical proximity of 
neighboring nucleosomes to MLL4, which enables MLL4-mediated H3K4me1/2 over a much 
broader region. 
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C/EBPβ is a lineage-determining TF for adipogenesis. It can bind to relatively closed 
chromatin and thus behaves as a pioneer factor in adipogenesis (Siersbaek et al., 2011). By 
ectopic expression of C/EBPβ in preadipocytes without inducing differentiation, we show that 
C/EBP  recruits and requires MLL4 to establish a subset of adipogenic enhancers. Our data is 
consistent with earlier reports that genomic binding of the lineage-determining TF PU.1 leads to 
H3K4me1 in macrophages and B cells and that ectopic expression of PU.1 in non-hematopoietic 
fibroblasts induces H3K4me1 on macrophage-specific enhancers (Ghisletti et al., 2010; Heinz et 
al., 2010). Although it remains to be determined whether MLL4 and/or MLL3 play a major role 
in establishing enhancers in macrophages, B cells and other cell types, the available results 
suggest that lineage-determining TFs recruit H3K4me1/2 methyltransferases to prime enhancer-
like regions in a particular cell type.  
Ectopic expression of C/EBP  in preadipocytes without differentiation only recovers a 
subset of endogenous C/EBP
+
MLL4
+
 enhancers, indicating that the recruitment of MLL4 to 
enhancers during adipogenesis involves additional mechanisms and factors. Because 
differentiation-dependent phosphorylation of C/EBP  increases its DNA binding activity, the 
optimal genomic binding of C/EBP  and the subsequent recruitment of MLL4 are likely 
dependent on induction of adipogenesis. Similarly, the binding of MyoD to myogenic enhancers 
on Myog locus is differentiation-dependent (Figure 7 - figure supplement 2B). The direct 
interaction between MLL3/4.com and PPAR  and the genomic co-localization of MLL4 with 
PPAR  and C/EBP  suggest that PPAR  and C/EBP  also play critical roles in recruiting MLL4 
to establish adipogenic enhancers.  
Motif analyses of MLL4 binding sites during adipogenesis and myogenesis have 
identified motifs of additional lineage-determining TFs, such as adipogenic TFs EBFs, GR and 
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NFIC and myogenic TFs TCF3, Runx1 and TEAD4 (Figure 4A). Future ChIP-Seq analyses will 
tell whether these additional lineage-determining TFs can recruit MLL4 to regions that are not 
bound by C/EBP / , PPAR  or MyoD. On the other hand, MLL4 is absent from many genomic 
regions that are occupied by C/EBP /  or PPAR  during adipogenesis or by MyoD in myocytes 
(Figure 4B and 4D), suggesting that lineage-determining TFs alone are not always sufficient for 
recruiting MLL4 to establish enhancers and that additional mechanisms and factors may be 
involved.  
Ectopic expression of C/EBP  in preadipocytes partially mimics the early phase of 
adipogenesis when PPARγ and C/EBPα have not been induced yet. Nevertheless, endogenous 
C/EBPβ co-localizes with MLL4 on active enhancers located on both PPAR  and C/EBP  gene 
loci (Figure 4 - figure supplement 1 and 2). Because C/EBPβ not only transcriptionally activates 
PPAR  and C/EBP  gene expression but also facilitates PPAR  and C/EBP  genomic binding 
during adipogenesis (Rosen et al., 2002; Siersbaek et al., 2011), our data suggests the following 
model on how MLL4 regulates adipogenesis (Figure 8F). The pioneer TF C/EBPβ recruits 
MLL4 to activate adipogenic enhancers on, and the subsequent induction of, PPARγ and C/EBPα 
expression. After the master adipogenic TFs PPARγ and C/EBP  are induced, they cooperate to 
recruit MLL4 to establish the downstream enhancer landscape critical for adipocyte gene 
expression.  
 In cell culture, MLL3 and MLL4 are partially redundant in adipogenesis. In mice, 
deletion of MLL4 alone causes severe defects in BAT development. Inactivating MLL3 in mice 
has been shown to decrease white adipose tissue size (Lee et al., 2008). These results suggest 
that while MLL4 is the dominant one during mouse embryonic development, MLL3 is partially 
redundant with MLL4 in mice. The critical roles of MLL3 and MLL4 in adipogenesis are 
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consistent with our previous report that PTIP, a component of the MLL3/4.com, is essential for 
PPAR  and C/EBP  expression and adipogenesis (Cho et al., 2009).  
 
How does MLL4 work on enhancers? 
The presence of H3K4me1 on enhancers often precedes the active enhancer mark 
H3K27ac and gene expression, suggesting that H3K4me1 broadly defines a window of future 
active enhancers (Calo and Wysocka, 2013). Consistently, our time-course ChIP assays revealed 
sequential appearances of H3K4me1/2 and H3K27ac on C/EBP
+
MLL4
+
 active enhancers on 
PPAR  gene locus in the early phase of adipogenesis (Figure 8 - figure supplement 1). Further, 
we show that the H3K4me1/2 methyltransferase MLL4 is required for H3K27ac, Mediator and 
Pol II on enhancers, which indicates that MLL4 is required for enhancer activation and suggests 
that MLL4 exerts its function in enhancer commissioning through H3K4me1/2. Collectively, our 
data suggests a stepwise model of enhancer activation during adipogenesis (Figure 8G). Step 1, 
pioneer TF binding. Pioneer TFs such as C/EBP  bind enhancer-like regions. Step 2, enhancer 
commissioning by MLL4. Lineage-determining TFs, such as C/EBP , PPAR  and C/EBP , 
cooperatively recruit MLL4 to perform H3K4me1/2 on enhancer-like regions. Step 3, enhancer 
activation by H3K27 acetyltransferase p300, followed by Pol II recruitment, establishment of 
enhancer-promoter interaction, and activation of cell-type-specific gene expression. Thus, the 
enhancer-associated H3K4me1/2 methyltransferase MLL4 appears to perform the opposite 
function of LSD1, an H3K4me1/2 demethylase required for decommissioning of embryonic stem 
(ES) cell-specific enhancers during ES cell differentiation (Whyte et al., 2012).  
 
MLL3/MLL4 mutations in diseases 
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Frequent loss-of-function mutations in MLL4 (sometimes called MLL2) and its homolog 
MLL3 have been identified in developmental diseases such as Kabuki syndrome (Ng et al., 
2010), congenital heart disease (Zaidi et al., 2013), and in cancers such as medulloblastoma 
(Jones et al., 2012; Parsons et al., 2011; Pugh et al., 2012), non-Hodgkin lymphomas (Morin et 
al., 2011; Pasqualucci et al., 2011), breast cancer (Ellis et al., 2012), and prostate cancer (Grasso 
et al., 2012). Our findings suggest that loss-of-function mutations in MLL3 and MLL4 would 
impair H3K4me1/2 on enhancers, which leads to defects in enhancer activation, cell-type-
specific gene expression and cell differentiation. Such a mechanism may contribute to the 
pathogenesis of these developmental diseases and cancers.    
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MATERIALS AND METHODS 
Plasmids and Antibodies 
The retroviral plasmids pMSCVhygro-PPARγ2, pWZLhygro-C/EBPβ and MSCVpuro-Cre have 
been described (Ge et al., 2008; Wang et al., 2010). MyoD cDNA was subcloned from 
MSCVpuro-MyoD into pWZLhygro. The shRNA sequence targeting mouse MLL4 gene 
(GCATGTTCTTCAAGGACAAGA) was cloned into lentiviral vector pLKO.1.  
The following homemade antibodies have been described: anti-UTX (Hong et al., 2007); 
anti-PTIP, anti-PA1#2, anti-MLL4#3 (Cho et al., 2009). Anti-C/EBPα (sc-61X), anti-C/EBPβ 
(sc-150X), anti-PPARγ (sc-7196X), and anti-MyoD (sc-760) were from Santa Cruz 
Biotechnology. Anti-Menin (A300-105A), anti-RbBP5 (AA300-109A) and anti-
MED1/TRAP220 (A300-793A) were from Bethyl Laboratories. Anti-H3K4me1 (ab8895) was 
from Abcam. Anti-Pol II (17-672) and anti-H3K4me3 (07-473) were from Millipore. Other 
histone methylation and acetylation antibodies have been described (Jin et al., 2011).  
 
Generation of Mouse Strains 
MLL3
+/- 
and MLL4
+/- 
mice were generated from BayGenomics gene trap ES cell lines following 
standard procedures at NIDDK Mouse Knockout Core (Stryke et al., 2003). MLL3
+/- 
mice were 
derived from ES cell line XM083, in which the gene trap vector pGT0lxf was inserted between 
exon 9 and 10 of one MLL3 allele. MLL4
+/- 
mice were derived from ES cell line XT0709, in 
which the gene trap vector pGT0lxf was inserted between exon 19 and 20 of one MLL4 allele.  
To generate MLL4 conditional KO mice, the loxP/FRT-flanked neomycin cassette was 
inserted at the 3' of exon 19 and the single loxP site was inserted at the 5' of exon 16. The 
targeted region includes exons 16-19 (Figure 1A). The MLL4
floxneo/+
 ES cell was injected into 
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blastocysts to obtain male chimera mice, which were crossed with wild type C57BL/6J females 
to screen for germ line transmission. Mice bearing germline transmission (MLL4
floxneo/+
) were 
crossed with FLP1 mice (Jackson no. 003946) to generate MLL4
f/+
 (i.e. MLL4
flox/+
) mice. 
MLL4
f/+
 mice were crossed with Myf5-Cre (Jackson no. 007893). The resulting MLL4
f/+
;Myf5-
Cre were then crossed with MLL4
f/f
 to generate MLL4
f/f
;Myf5-Cre mice. Deletion of exons 16-19 
by Cre causes open reading frame shift and creates a stop codon in exon 20. The resulting MLL4 
KO allele encodes a truncated MLL4 protein lacking the C-terminal ~4,200aa. For genotyping 
the MLL4 alleles, allelic PCR was developed as shown in Figure 1A-B.  P1:5'- 
GTTCACTCAGTGGGGCTGTG -3’; P2: 5'- ATTGCATCAGGCAAATCAGC -3'; P3: 5'- 
GCAGAAGCCTGCTATGTCCA -3’. Genotyping of Myf5-Cre was done by PCR using the 
following 3 primers: 5'-CGTAGACGCCTGAAGAAGGTCAACCA-3', 5'-
CACATTAGAAAACCTGCCAACACC-3', and 5'-ACGAAGTTATTAGGTCCCTCGAC-3'. 
PCR amplified wild-type (603bp) and Myf5-Cre allele (400bp).  
All mouse work was approved by the Animal Care and Use Committee of NIDDK, NIH. 
 
Histology and Immunohistochemistry 
E18.5 embryos were dissected out by Cesarean section and fixed in 4% paraformaldehyde 
overnight at 4 C. Embryos were further dehydrated and embedded in paraffin and sectioned at 7-
10µm with a microtome. H&E staining and immunohistochemistry (IHC) on paraffin sections 
were done as described (Feng et al., 2010). The primary antibodies used for IHC were 1:20 
dilution of anti-Myosin (Developmental Studies Hybridoma Bank, MF20) and 1:400 dilution of 
anti-UCP1 (Abcam ab10983). Fluorescent secondary antibodies used were Alexa Fluor 488 goat 
anti-mouse IgG2b and Alexa Fluor 555 goat anti-rabbit IgG (Molecular Probes).  
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Immortalization of Primary Brown Preadipocytes, Virus Infection, Adipogenesis and 
Myogenesis Assays 
Primary brown preadipocytes were isolated from interscapular BAT of E18.5 embryos and were 
immortalized with SV40T-expressing retroviruses pBabepuro-large T as described (Wang et al., 
2010). Adenoviral infection of preadipocytes was done at 50 moi. Adipogenesis of immortalized 
brown preadipocytes and 3T3-L1 white preadipocyte cell line was done as described (Wang et 
al., 2013). PPARγ- or C/EBPβ-stimulated adipogenesis and MyoD-stimulated myogenesis were 
done as described (Ge et al., 2002). Myogenesis was induced in near-confluent cells.  
 
qPCR 
Total RNA extraction and qRT-PCR were done as described (Cho et al., 2009). Taqman probe 
for MLL3 (assay ID Mm01156965_m1) was from Applied Biosystems. qRT-PCR of MLL4 was 
done using SYBR green primers: forward 5'- GCTATCACCCGTACTGTGTCAACA-3' and 
reverse 5'-CACACACGATACACTCCACACAA-3'. Taqman probes for PPARγ1 and PPARγ2 
and other SYBR green primers for qRT-PCR have been described (Wang et al., 2013). SYBR 
green primers for ChIP-qPCR are listed in Supplementary File 1B.  
 
ChIP-Seq and RNA-Seq 
ChIP was performed by following a protocol from Myers’ laboratory 
(http://www.hudsonalpha.org/myers-lab/protocols) with modifications. Cells were crosslinked 
with 1-2% formaldehyde for 10 min at room temperature. Crosslinking reaction was stopped by 
adding 125mM glycine. Cells were washed with cold PBS twice. 2x10
7
 cells were collected in 
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10 ml Farnham lysis buffer (5mM PIPES pH 8.0 / 85mM KCl / 0.5% NP-40, supplemented with 
protease inhibitors) and centrifuged at 4,000 g for 5 min at 4°C. Cell pellet was washed with 10 
ml Farnham lysis buffer, followed by centrifugation. Resulting nuclear pellet was resuspended in 
1 ml TE buffer (10mM Tris-Cl pH 7.7 / 1mM EDTA, supplemented with protease inhibitors) and 
sonicated for 17 min (30 sec on/off cycle). Lysates were supplemented with detergents to make 
1X RIPA buffer (10mM Tris-Cl pH 7.7 / 1mM EDTA / 0.1 % SDS / 0.1 % Na-DOC / 1 % triton 
X-100) and centrifuged to remove debris. For each ChIP, 6-8µg antibodies were prebound to 50 
µl Dynabeads Protein A (100.02D, Invitrogen) overnight at 4°C. Next day, antibody-beads 
complex was added to chromatin from 2x10
7
 cells and further incubated overnight at 4°C. Beads 
were washed twice with RIPA buffer, twice with RIPA + 0.3M NaCl, twice with LiCl buffer 
(50mM Tris-Cl pH 7.5 / 250mM LiCl / 0.5 % NP-40 / 0.5 % Na-DOC) and twice with PBS. 
DNA was eluted and reverse crosslinked in 200µl elution buffer (1% SDS / 0.1M NaHCO3, 
supplemented with 20µg proteinase K) overnight at 65°C. DNA was purified by QIAquick PCR 
Purification Kit (QIAGEN) and quantified. DNA and libraries were constructed as described 
(Wei et al., 2012). All ChIP-Seq and RNA-Seq samples were sequenced on Illumina HiSeq 2000.  
 
Computational Analysis 
1. Summary of computational analysis: Identification of ChIP-enriched regions was performed 
using the island approach “SICER” (Zang et al., 2009). Gene ontology (GO) study was carried 
out using DAVID (Huang et al., 2009). Motif search around MLL4 binding regions was 
conducted using SeqPos (He et al., 2010).  
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2. Illumina pipeline analysis for ChIP-Seq and RNA-Seq data: The sequence reads were of 
50bp in length and aligned to reference genome assembly NCBI37/mm9. The output of the 
Illumina Analysis Pipeline was converted to browser extensible data (BED) files detailing the 
genomic coordinates of each mapped read. To visualize the data on the UCSC genome browser 
(Karolchik et al., 2008), reads were collected and converted to wiggle (WIG) format using in-
house script. The numbers of mapped reads are listed in Supplementary File 1A. 
 
3. Gene expression calculation using RNA-Seq data: For RNA-Seq datasets, we collected only 
reads that locate on exons as annotated in NCBI Reference Sequence Database (RefSeq) for 
assembly mm9, and calculated reads per kilobase per million (RPKM) for each gene as measure 
of expression level. Genes with RNA-Seq exonic RPKM>1 were regarded as expressed. In 
comparing gene expression levels before (D0, day 0) and during (D2, day 2) adipogenesis (or 
comparing gene expression levels in preadipocyte vs. after myogenesis), we set a fold change 
cutoff of 2.5 to identify up-regulated and down-regulated genes. MLL4-dependent genes were 
defined as genes with over 2.5 fold down-regulation in MLL4-deficient cells (MLL3
-/-
MLL4
-/-
)  
compared with control cells (MLL3
-/-
) (Figure 2D and 2I). Out of 14,902 genes expressed at D0 
or D2 in adipogenesis, 1,531 were MLL4-dependent. Meanwhile, in the 1,302 up-regulated 
genes, 588 were MLL4-dependent. The p-value for the enrichment of MLL4-dependent genes in 
up-regulated genes was 1.4E-268 using hypergeometric test. The same approach was used for 
calculating the significance of MLL4-dependent induction in myogenesis. Genome-wide, 1,155 
out of 16,805 expressed genes were MLL4-dependent. On the other hand, 836 out of 2,774 up-
regulated genes were MLL4-dependent. The significance of MLL4-dependency in upregulated 
genes was p < 1E-300 using hypergeometric test. GO studies were carried out using DAVID 
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with the whole genome as background, and for each group of genes the GO terms with p-value 
<= 10
-7
 were listed (Figure 2E and 2J).   
 
4. Identification of ChIP-enriched regions: To eliminate background noise in ChIP-Seq 
datasets, we determined ChIP-enriched regions for each ChIP-Seq sample using the SICER 
method (Zang et al., 2009). In particular, to eliminate non-specific binding of MLL4 antibody, 
we compared MLL4 ChIP-Seq sample from MLL4-deficient (MLL3
-/-
MLL4
-/-
) cells against that 
from control (MLL3
-/-
) cells, and kept only the identified MLL4 binding regions with enrichment 
level significantly higher in control cells than in the MLL4-deficient cells, with an estimated 
false discovery rate (FDR) of less than 10
-15
. The same FDR threshold was also applied to 
C/EBPα and C/EBPβ ChIP-Seq samples when analyzed against the input libraries. For PPARγ 
ChIP-Seq at D0 (day 0) and D2 (day 2) of brown adipogenesis, MLL4 ChIP-Seq in C/EBPβ 
over-expressing brown preadipocytes, and MLL4 and MyoD ChIP-Seq in myocytes, the FDR 
threshold was set to be 10
-5
 due to the limited coverage of sequenced reads. For the ChIP-Seq 
datasets of histone modifications (H3K4me1/2/3 and H3K27ac), the window size was chosen to 
be 200bp and the FDR threshold was chosen to be 10
-3
. For the ChIP-Seq datasets of MLL4, Pol 
II, MyoD and adipogenic factors (C/EBPα, C/EBPβ, and PPARγ), the window size was chosen 
to be 50bp. Another required parameter in SICER, gap size, was chosen to be equal to 1 window.  
 
5. Genome-wide co-localization study: Specific MLL4-enriched regions identified at D0, D2, 
D7 (day 0, 2, 7) during adipogenesis as well as in myocytes were compared, and co-localization 
was defined as two regions overlapping for at least 1bp (Figure 3A-B). All D0 MLL4 regions, 
D2 MLL4 regions that did not overlap with D0 regions, D7 MLL4 regions that didn’t overlap 
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with either D0 or D2, and identified MLL4 peaks in myocytes but not in preadipocytes, were 
regarded as emergent MLL4 binding sites. Top 2,000 in each group as ranked by FDR against 
MLL4-deficient control were used later for GO and motif analyses. Each of the top 2,000 
emergent MLL4 binding sites was assigned to its closest transcription start sites (TSS). The 
resulting gene list was imported into DAVID for GO analysis. The enriched GO terms in 
biological process with p-value less than 10
-5
 were listed (Figure 3D). The same top emergent 
MLL4 sites were used as input to SeqPos (He et al., 2010) for motif search. All motifs found 
with calculated p-value less than 10
-10
 were listed (Figure 4A). By the same 1bp-overlapping 
definition of co-localization, MLL4 binding sites at D2 were compared with C/EBPα, C/EBPβ, 
and PPARγ binding sites. Given the motif similarity and functional redundancy between C/EBPα 
and C/EBPβ, we first calculated the union of their binding sites and regarded them as C/EBPs 
(Figure 4B). The heat maps were generated with 50bp resolution and ranked according to the 
intensity of MLL4 at the center of 400bp window (Figure 4C). Using the same approach we 
checked co-localization between MLL4 and MyoD in myocytes (Figure 4D-E).  
 
6. Identification of enhancers and promoters during adipogenesis: By definitions described 
in Figure 5A, we identified enhancers and promoters along the genome. The definitions were 
applied in a mutually exclusive way, i.e., for each genomic region, we first checked whether it 
was promoter or enhancer (or others), then further pinned it down to active or silent ones (Figure 
5C). The total length of the all active enhancers was 43% of total length of all enhancers and 
promoters. On the other hand, 9,642 of 11,948 (80.6%) MLL4 binding sites on enhancers and 
promoters were located on active enhancers. Therefore, the significance of MLL4 enrichment on 
active enhancers was p < 1E-300 using binomial test. Average profiles were plotted using the 
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number of ChIP-Seq reads (normalized to the size of each library) in 5bp bins from the center of 
each regulatory element to 10kb on both sides. The centers of regulatory elements were defined 
as the corresponding TSSs for promoters and the centers of H3K4me1 enriched regions for 
enhancers (Figure 5B). Furthermore, the active adipogenic enhancers were defined as C/EBPα, 
C/EBPβ, and PPARγ binding sites that were on active enhancers. Again C/EBP refers to the 
union of C/EBPα and C/EBPβ.  
 
Genome-wide, out of the 26,348 C/EBP sites at D2, 8,235 (31.3%) were MLL4
+
. On the other 
hand, out of the 10,061 C/EBP sites on active enhancers, 5,762 (57.3%) were MLL4
+
. The 
significance for the preferential enrichment of the co-localization of MLL4
 
with C/EBP on active 
enhancers was p < 1E-300 using hypergeometric test. Similarly, genome-wide, out of the 6,148 
PPARγ sites at D2, 3,461 (56.3%) were MLL4+. On the other hand, out of the 3,182 PPARγ sites 
on active enhancers, 2,544 (80.0%) were MLL4
+
. The significance for the preferential 
enrichment of co-localization of MLL4
 with PPARγ on active enhancers was p < 1E-300 using 
hypergeometric test. 
 
The heat maps were generated with 50bp resolution and ranked according to the co-localization 
of C/EBPα, C/EBPβ, and PPARγ binding sites (Figure 5D). The 6,342 adipogenic enhancers that 
co-localize with MLL4 were used to profile various histone modifications, Pol II and MED1 in 
both control and MLL4-deficient cells (Figure 7A). Each active adipogenic enhancer was 
assigned to the nearest TSS within 1000kb, and the corresponding fraction of genes that were 
induced (fold change > 2.5) at D2 of adipogenesis and gene expression fold change (in base 2 
logarithm) in KO cells were plotted using box plot, with outliers not shown to highlight the 
 31 
 
majority (Figure 7B-C). In Figure 7B and 7C, we classified genes associated with adipogenic 
enhancers into three mutually exclusive groups: C/EBP
+
PPAR  , C/EBP PPAR
+
, or 
C/EBP
+
PPAR
+
. A gene might be simultaneously associated with adipogenic enhancers with 
different patterns of TF occupation (i.e., C/EBP
+
PPAR  , C/EBP PPAR
+
, or C/EBP
+
PPAR
+
), 
resulting in ambiguity in designation. To resolve this ambiguity, we adopted the following rule: a 
promoter (and the corresponding gene) was categorized as C/EBP
+
PPAR
+ 
if at least one of its 
associated adipogenic enhancer was C/EBP
+
PPAR
+
. A promoter was categorized as 
C/EBP
+
PPAR  or C/EBP PPAR
+
, if none of the associated adipogenic enhancer was 
C/EBP
+
PPAR
+
, but at least one of them is C/EBP
+
PPAR  or C/EBP PPAR
+
. Similarly, a 
promoter is categorized as MLL4  if none of the associated adipogenic enhancer is MLL4
+
.  
 
7. Identification of recovered C/EBPβ+ active adipogenic enhancers in C/EBPβ over-
expressing preadipocytes: Among the 4, 965 C/EBPβ+MLL4+ active enhancers identified at D2 
of adipogenesis, we found 3,309 of them had C/EBPβ binding in C/EBPβ over-expressing 
preadipocytes. 666 of 3,309 had MLL4 binding as well (Figure 8B). 591 of them also had 
H3K4me1 and H3K27ac enriched and were regarded as recovered C/EBPβ+MLL4+ active 
enhancers (Figure 8C). Based on the MLL4 enrichment in vector-expressing preadipocytes, we 
grouped recovered C/EBPβ+MLL4+ active enhancers into two categories, with MLL4 in vector-
expressing preadipocytes (premarked) and without MLL4 in vector-expressing preadipocytes (de 
novo). We computed C/EBPβ, MLL4, H3K4me1 and H3K27ac enrichment intensities (as by 
normalized ChIP-Seq read count) in control and MLL4-deficient preadipocytes, with or without 
C/EBPβ over-expression (Figure 8C). We found that in both groups, H3K4me1 and H3K27ac 
were induced in C/EBPβ over-expressing cells, and the induction was MLL4-dependent: in using 
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MLL4-deficient cells, over 95% of H3K4me1 islands corresponding to the recovered C/EBPβ+ 
active adipogenic enhancers exhibited significant (FDR < 10
-3
) decreased enrichment (Figure 
8D).  
 
8. Identification of enhancers and promoters during myogenesis: By definitions described in 
Figure 5A, we identified enhancers and promoters along the genome. Then we checked the 
binding profile of MLL4 and MyoD on genomic regulatory elements to reveal the preferential 
binding pattern. Furthermore, we identified MyoD
+
 active enhancers, and generated heat maps 
for MyoD and MLL4 at 50bp resolution (Figure 5 - figure supplement 1A-C). Genome-wide, 
10,699 out of the 30,496 MyoD binding sites were MLL4
+
. On the other hand, 5,228 out of 
8,091 MyoD binding sites on active enhancers were MLL4
+
. The significance for the preferential 
enrichment of co-localization of MLL4
 
with MyoD on active enhancers was p < 1E-300 using 
hypergeometric test. The 5,228 active myogenic enhancers that co-localized with MLL4 were 
used to profile various histone modifications in both control and MLL4-deficient cells (Figure 7 - 
figure supplement 2A). Each active myogenic enhancer was assigned to the nearest TSS within 
1000kb, and the corresponding gene expression fold change (in base 2 logarithm) in MLL4-
deficient cells were plotted using box plot, with outliers not shown to highlight the majority 
(Figure 7 - figure supplement 2C).  
 
Accession Numbers 
All datasets described in this paper, including 8 RNA-Seq samples, 62 ChIP-Seq samples and 12 
ChIP-Seq inputs, have been deposited in NCBI Gene Expression Omnibus under access # 
GSE50466. 
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FIGURE LEGENDS 
Figure 1. MLL4 Is required for brown adipose tissue and muscle development. 
(A–B) Generation of MLL4 conditional KO mice (MLL4f/f). (A) Schematic representation of 
mouse MLL4 wild-type (WT) allele, targeted allele, conditional KO (flox) allele and KO allele. 
In the targeted allele, a single loxP site was inserted in the intron before exon 16. A neomycin 
(neo) selection cassette flanked by FRT sites and the second loxP site was inserted in the intron 
after exon 19. The locations of PCR genotyping primers P1, P2 and P3 are indicated by arrows. 
(B) PCR genotyping of cell lines using mixtures of P2 + P3 or P1 + P3 primers. The genotypes 
are indicated at the top. 
(C) Genotype of E18.5 embryos isolated from crossing MLL4
f/+
;Myf5-Cre with MLL4
f/f 
mice. 
The expected ratios of the four genotypes are 1:1:1:1. MLL4
f/f
;Myf5-Cre mice died immediately 
after cesarean section because of breathing malfunction due to defects in muscles of the rib cage. 
(D) Representative pictures of E18.5 embryos of the indicated genotypes.  
(E) E18.5 embryos were sagittally sectioned along the midline. The sections of the 
cervical/thoracic area indicated in the schematic were stained with H&E (upper panels) or with 
antibodies recognizing BAT marker UCP1 (green) and skeletal muscle marker Myosin (red) 
(lower panels). Scale bar = 800μm.  
 
Figure 1 - figure supplement 1. Generation of MLL3 and MLL4 whole body KO mice.  
(A) Protein domains in yeast SET1 and the homologous mouse SET1-like H3K4 
methyltransferases. 
(B–E) Generation of MLL3 and MLL4 whole body KO mice. Wild type (WT) and KO alleles of 
MLL3 and MLL4 genomic loci are shown in (B) and (D), respectively. The exons flanking the 
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gene trap vectors are numbered. MLL3 KO mice are perinatal lethal (C), while MLL4 KO mice 
are early embryonic lethal (E). 
 
Figure 1 - figure supplement 2. Confirmation of MLL4 deletion.  
Immortalized MLL3
-/-
MLL4
f/f
 brown preadipocytes were infected with adenoviral GFP or Cre. 
(A) Genome browser view of RNA-Seq analysis on MLL4 gene locus. The targeted exons 16 – 
19 are highlighted in red box. 
(B) Deletion of MLL4 disrupts MLL4 complex in cells. Nuclear extracts were incubated with 
MLL4, UTX, PTIP or PA1 antibody. The immunoprecipitates were analyzed by Western 
blotting using antibodies indicated on the right.  
 
Figure 2. MLL4 controls induction of cell-type-specific genes during differentiation. 
(A-E) Adipogenesis of MLL3
-/-
MLL4
f/f
 brown preadipocytes. 
(A-B) MLL4 is required for adipogenesis. Immortalized MLL3
-/-
MLL4
f/f
 brown preadipocytes 
were infected with adenoviral GFP or Cre, followed by adipogenesis assay. 
(A) Six days after induction of differentiation, cells were stained with Oil Red O. Upper panels, 
stained dishes; lower panels, representative fields under microscope.  
(B) qRT-PCR of MLL4, PPAR  and C/EBP  expression at indicated time points of adipogenesis. 
Quantitative PCR data in all figures are presented as means ± SD. D1, day 1.  
(C) MLL4 is required for C/EBPβ- and PPAR -stimulated adipogenesis. MLL3-/-MLL4f/f brown 
preadipocytes were infected with retroviruses expressing vector (vec), C/EBPβ or PPAR . After 
hygromycin selection, cells were infected with adenoviral GFP or Cre, followed by adipogenesis 
assay. 
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(D-E) MLL4 is required for induction of cell-type-specific genes during adipogenesis. 
Adipogenesis was done as in (A). Cells were collected before (day 0) and during (day 2) 
adipogenesis for RNA-Seq.  
(D) Schematic of identification of MLL4-dependent and –independent up-regulated genes during 
adipogenesis. The threshold for up- or down-regulation is 2.5-fold.  
(E) Gene ontology (GO) analysis of gene groups defined in (D). 
(F-J) MLL4 is required for MyoD-stimulated myogenesis. Immortalized MLL3
-/-
MLL4
f/f
 brown 
preadipocytes were infected with retroviruses expressing Vec or MyoD. After hygromycin 
selection, cells were infected with adenoviral GFP or Cre, followed by myogenesis assay. (F) 
Western blot analysis of MyoD expression before differentiation. RbBP5 was used as a loading 
control. The asterisk indicates a non-specific band. (G) Five days after induction of 
differentiation, cell morphologies were observed under microscope. (H) qRT-PCR analysis of 
myogenic gene expression after differentiation. 
(I–J) MLL4 is required for induction of cell-type-specific genes during myogenesis. Brown 
preadipocytes and myocytes were collected for RNA-Seq.  
(I) Schematic of identification of MLL4-dependent and –independent up-regulated genes during 
myogenesis. The threshold for up- or down-regulation is 2.5-fold.  
(J) GO analysis of gene groups defined in (I). 
 
Figure 2 - figure supplement 1. MLL4 is required for adipogenesis. 
(A-C) MLL3 is dispensable for adipogenesis of brown preadipocytes. Brown preadipocytes 
isolated from MLL3
+/+
 and MLL3
-/-
 E18.5 embryos were immortalized by retroviruses expressing 
SV40T. Cells were induced for adipogenesis for 6 - 7 days. (A) qRT-PCR analysis of MLL3 
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expression before adipogenesis. (B) Oil Red O staining after adipogenesis. (C) qRT-PCR 
analysis of gene expression before (D0) and after (D6) adipogenesis. 
(D–F) Single KO of MLL4 leads to reduced adipogenesis. (D) qRT-PCR analysis of Cre-
mediated MLL4 deletion before adipogenesis. (E) Oil Red O staining after adipogenesis. (F) 
qRT-PCR analysis of gene expression at indicated time points during adipogenesis.  
(G–H) Deletion of MLL4 does not affect growth of immortalized preadipocytes. (G) qRT-PCR 
analysis of MLL4 deletion in Cre-infected MLL3
-/-
MLL4
f/f
 preadipocytes. (H) Cell growth curves. 
(I) qRT-PCR of BAT-specific PRDM16 and UCP1 expression during adipogenesis. 
(J) Western blot analyses of retroviral C/EBPβ and PPAR  expression in adenoviral GFP- or 
Cre-infected MLL3
-/-
MLL4
f/f
 brown preadipocytes before adipogenesis. RbBP5 was used as a 
loading control. 
(K-M) Knockdown of MLL4 inhibits adipogenesis of 3T3-L1 white preadipocytes. 3T3-L1 cells 
were infected with lentivirus shRNA targeting MLL4 or control (Con) virus, followed by 
adipogenesis assay. (K) qRT-PCR confirmation of MLL4 knockdown before adipogenesis. (L) 
Oil red O staining after adipogenesis. (M) qRT-PCR analysis of gene expression before (D0) and 
after (D6) adipogenesis. 
(N-P) MLL4 is required for PPAR -stimulated adipogenesis of MEFs. 3T3-immortalized MLL3
-
/-
MLL4
f/f
 MEFs were infected with retroviruses MSCVhyg-PPAR , followed by infection of 
MSCVpuro-Cre. Adipogenesis was induced with PPAR  ligand Rosiglitasone (Rosi) or vehicle 
DMSO alone. (N) Western blot analysis of retroviral PPAR  expression before adipogenesis. 
GAPDH was used as a loading control. (O) Oil red O staining and (P) qRT-PCR analysis of gene 
expression after adipogenesis. 
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Figure 2 - figure supplement 2. Confirmation of RNA-Seq data by qRT-PCR. 
 
Figure 3. Cell-type- and differentiation-stage-specific genomic binding of MLL4. 
Adipogenesis and myogenesis were done as in Figure 2A and 2F-G, respectively. Cells were 
collected for ChIP-Seq analysis of MLL4.  
(A) Venn diagram of MLL4 binding regions at day 0 (preadipocytes), day 2 (during adipogenesis) 
and day 7 (adipocytes) of adipogenesis. 
(B) Venn diagram of MLL4 binding regions in adipocytes and myocytes. 
(C) ChIP-Seq profiles of MLL4 binding on gene loci encoding PPAR  and myogenin (Myog) at 
indicated time points and cell types. 
(D) GO analysis of genes associated with emergent MLL4 binding regions at indicated time 
points and cell types. 
 
Figure 3 - figure supplement 1. MLL4 binds to adipogenesis genes. 
ChIP-Seq of MLL4 was performed during adipogenesis as described in Figure 2. (A–E) MLL4 
binding on adipogenic genes at day 2 of adipogenesis. In each panel, the top 2 tracks show the 
raw data while the bottom track shows the filtered data. (F–J) MLL4 binding on C/EBPa (F), 
Klf15 (G), Fabp4 (H), LPL (I) and UCP1 (J) gene loci during adipogenesis. (K) MLL4 exhibits 
little binding to C/EBPβ locus during adipogenesis.  
 
Figure 3 - figure supplement 2. ChIP-qPCR confirmation of ChIP-Seq data. 
(A) Schematic of genomic locations of MLL4
+
 enhancers on PPAR , C/EBP , Fabp4 (aP2) and 
Prdm16 loci. E, enhancer. 
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(B) ChIP-qPCR confirmation of ChIP-Seq data on MLL4
+
 enhancers. 
 
Figure 4. Genomic co-localization of MLL4 with lineage-determining TFs during 
differentiation. 
(A) Adipogenic TF binding motifs are enriched at MLL4 binding regions during adipogenesis 
while myogenic TF binding motifs are enriched at MLL4 binding regions in myocytes. Top 
2,000 emergent MLL4 binding regions at each time point were used for motif analysis. Only TFs 
that are expressed at the indicated cell type or differentiation stage are included. 
(B - C) Venn diagram (B) and heat maps (C) of genomic co-localization of MLL4 with C/EBPs 
(C/EBPα or β) and PPAR  at day 2 of adipogenesis. 
(D - E) Venn diagram (D) and heat maps (E) of genomic co-localization of MLL4 with MyoD in 
myocytes.   
(F) MLL4 physically interacts with C/EBPβ during adipogenesis. Nuclear extracts prepared at 
day 2 of adipogenesis were immunoprecipitated with MLL4 antibody. The immunoprecipitates 
were analyzed by Western blot using antibodies against MLL3/MLL4 complex components 
(UTX, PTIP, RbBP5 and PA1), Menin, or C/EBP . 
 
Figure 4 - figure supplement 1. ChIP-Seq and RNA-Seq data on PPAR  gene during 
adipogenesis.  
D0 and D2, day 0 and day 2. 
 
Figure 4 - figure supplement 2. ChIP-Seq and RNA-Seq data on C/EBPα gene during 
adipogenesis.  
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Figure 4 - figure supplement 3. PPAR  interacts with MLL3/MLL4-containing H3K4 
methyltransferase complex in cells. 
(A) Anti-FLAG M2 agarose was used to immunoprecipitate from nuclear extracts of HeLaS cells 
stably expressing FLAG-tagged PPAR  (F-PPAR ) (Ge et al., 2008). The immunoprecipitates 
were analyzed by Western blot using antibodies indicated on the right. MLL1
C
, MLL1 c-terminal 
fragment. 
(B) Anti-PPAR  antibody or IgG were used to immunoprecipitate from nuclear extracts of 
HeLaS cells stably expressing F-PPAR . The immunoprecipitates were subjected to HMT assay 
on an histone H3 peptide as described previously (Cho et al., 2007). 
 
Figure 5. MLL4 co-localizes with lineage-determining TFs on active enhancers during 
differentiation. 
ChIP-Seq analyses of MLL4, TFs, H3K4me1/2/3 and H3K27ac were done at day 2 of 
adipogenesis.  
(A) Table depicting histone modifications used to define gene regulatory elements. TSS, 
transcription start site. 
(B–C) MLL4 is mainly localized on active enhancers during adipogenesis.  
(B) Average binding profiles of MLL4, adipogenic TFs C/EBPα, C/EBPβ and PPAR , and RNA 
polymerase II (Pol II) around the center of each type of gene regulatory elements.   
(C) Pie charts depicting the genomic distributions of MLL4, C/EBPα, C/EBPβ, PPAR  and Pol 
II binding regions. 
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(D) MLL4 co-localizes with adipogenic TFs on active enhancers during adipogenesis. The 
binding profiles of C/EBPα, C/EBPβ, PPAR  and MLL4 on the 3 types of adipogenic enhancers 
(C/EBP
+
PPAR , C/EBP PPARγ+ and C/EBP+PPARγ+) are shown in heat maps. Adipogenic 
enhancers are defined as active enhancers bound with C/EBPα, C/EBPβ or PPAR  at day 2 of 
adipogenesis. 
  
Figure 5 - figure supplement 1. MLL4 co-localizes with lineage-determining TFs on active 
enhancers during myogenesis.  
MyoD-stimulated myogenesis of brown preadipocytes was done as in Figure 2. 
(A) Average binding profiles of MLL4 and MyoD around the center of each type of gene 
regulatory elements in myocytes. 
(B) Pie charts depicting the genomic distributions of MLL4 and MyoD binding regions in 
myocytes. 
(C) MLL4 co-localizes with MyoD on active enhancers in myocytes. Heat maps illustrating the 
binding of MyoD and MLL4 on MyoD
+
 active enhancers are shown. 
 
Figure 6. MLL4 Is a major H3K4 mono- and di-methyltransferase in cells. 
(A–B) In vitro histone methyltransferase (HMT) assay. 
(A) SET1A/SET1B complex (SET1A/B.com) and MLL3/MLL4 complex (MLL3/4.com) that 
were affinity-purified from 293T nuclear extracts were incubated with core histones in an HMT 
assay for 3h, followed by Western blot analysis.  
(B) Time-course HMT assay with MLL3/4.com.  
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(C) MLL3
-/-
MLL4
f/f
 brown preadipocytes were infected with adenoviral GFP or Cre as in Fig. 2. 
Cells were collected at day 0 and day 2 of adipogenesis for Western blot analysis of histone 
modifications.  
(D) Western blot analysis of histone modifications in MLL3
-/-
MLL4
-/- 
HCT116 human colon 
cancer cells. 
(E) 87.7% of MLL4-binding regions at day 2 of adipogenesis were marked by H3K4me1/2 as 
revealed by ChIP-Seq analyses of MLL4 and H3K4me1/2.  
 
Figure 6 - figure supplement 1. MLL3 and MLL4 are H3K4 mono- and di-
methyltransferases in mammalian cells.  
(A) Western blot analyses of histone modifications in MLL3
-/-
 brown preadipocytes.  
(B) Western blot analyses of histone modifications before and after MyoD-stimulated 
myogenesis. Pre-ad, preadipocytes.  
 
Figure 7. MLL4 Is required for enhancer activation during differentiation. 
MLL3
-/-
MLL4
f/f
 brown preadipocytes were infected with adenoviral GFP or Cre as in Figure 2. 
Cells were collected at day 0 and day 2 of adipogenesis for ChIP-Seq of H3K4me1/2/3, 
H3K27ac, MED1 and Pol II, and RNA-Seq. 
(A) Deletion of MLL4 dramatically decreases H3K4me1/2, H3K27ac, MED1 and Pol II levels on 
MLL4 positive (MLL4
+
) adipogenic enhancers. Average profiles of histone modifications, 
MED1 and Pol II on MLL4
+
 adipogenic enhancers are shown. 
(B) MLL4 promotes induction of genes associated with MLL4
+
 adipogenic enhancer during 
adipogenesis. 
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(C) Deletion of MLL4 reduces expression of MLL4
+
 adipogenic enhancer-associated genes. 
Gene expression fold changes were obtained by comparing Cre-infected with GFP-infected cells 
at day 2 of adipogenesis and are shown in the box plot.  
 
Figure 7 - figure supplement 1. MLL4 is required for H3K4me1/2 on MLL4
+
 promoters. 
The average profiles of H3K4me1/2/3 levels on the 480 (29 silent plus 451 active) MLL4
+
 
promoters identified during adipogenesis (see Figure 5C) are shown.  
 
Figure 7 - figure supplement 2. MLL4 is required for enhancer activation during 
myogenesis.  
MyoD-stimulated myogenesis of brown preadipocytes was done as in Figure 2.  
(A) Deletion of MLL4 markedly decreases H3K4me1 and H3K27ac levels on MLL4
+
 MyoD
+
 
active enhancers. Average profiles of histone modifications on MLL4
+
 MyoD
+
 active enhancers 
are shown. 
(B) ChIP-Seq of MyoD, MLL4, H3K4me1, H3K4me3 and H3K27ac on Myog gene locus is 
visualized on UCSC genome browser. Myo, myocytes. 
(C) Deletion of MLL4 reduces expression of MLL4
+
 MyoD
+
 active enhancer-associated genes. 
Gene expression fold changes were obtained by comparing adenoviral Cre-infected with GFP-
infected cells in myocytes and are shown in the box plot. 
 
Figure 8. C/EBP  recruits and requires MLL4 to establish a subset of adipogenic 
enhancers. 
MLL3
-/-
MLL4
f/f
 brown preadipocytes were infected with retroviral C/EBPβ or Vec only, and then 
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infected with adenoviral GFP or Cre. Cells were collected 2 days after confluence without 
induction of differentiation for Western blot (A) and for ChIP-Seq of C/EBP , MLL4, H3K4me1 
and H3K27ac (B – E). 
(A) Western blot analyses of C/EBPβ expression and histone modifications. Nuclear protein 
RbBP5 was used as a loading control. 
(B) Ectopic expression of C/EBPβ in undifferentiated preadipocytes leads to MLL4 binding on a 
subset of C/EBPβ+ MLL4+ active enhancers identified at day 2 of adipogenesis. 
(C) Heat maps of the relative signals of C/EBPβ, MLL4, H3K4me1 and H3K27ac on the 
recovered C/EBPβ+ MLL4+ active enhancers. 
(D) MLL4 is required for H3K4me1 on the recovered C/EBPβ+ MLL4+ active enhancers. 
(E) Genome browser view of ectopic C/EBPβ-induced MLL4 binding as well as H3K4me1 and 
H3K27ac on PPAR  locus. 
(F) Model depicting the role of MLL4 in transcriptional regulation of adipogenesis. The early 
adipogenic TF C/EBPβ serves as a pioneer TF and recruits MLL4 to establish active enhancers 
on PPAR  and C/EBPα loci. After PPAR  and C/EBPα are induced, they recruit MLL4 and 
cooperate with other adipogenic TFs to shape the enhancer landscape important for adipocyte 
gene expression. 
(G) Model depicting the role of MLL4 in the step-wise enhancer activation.  
 
Figure 8 - figure supplement 1. Time-course ChIP-qPCR on C/EBPβ+MLL4+ enhancers on 
PPAR  gene. 
(A) Schematic of C/EBPβ+MLL4+ adipogenic enhancers 1, 2 and 3 (E1, E2 and E3) on PPAR  
gene locus.   
 49 
 
(B) Time-course ChIP-qPCR on C/EBPβ+MLL4+ enhancers on PPAR  gene locus at 0, 2, 4, 8, 
12, 24 and 48h after induction of adipogenesis in wild type brown preadipocytes. For clarity, 
only the upper half of error bars are shown. 
 
Supplementary File 1A. Mapped read counts in RNA-Seq and ChIP-Seq. 
 
Supplementary File 1B. List of SYBR Green primers for ChIP-qPCR   






















